Report Company Directory

BioForce Nanosciences Holdings

• Element Acquisition Corporation Announces Formation of Investment Committee by GlobeNewsWire
• Bioforce Nanosciences Holdings, Inc. Announces Its 1 for 5 Reverse Stock Split, Effective February 28, 2020 by GlobeNewsWire
• BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) Becomes Fully Reporting Per US SEC 1934 Act Rules by GlobeNewsWire

Biofrontera

• Biofrontera AG: 1 director by SmartInsider
• Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs by GlobeNewsWire
• Biofrontera reports preliminary revenue for the month of August 2021 by GlobeNewsWire
• Biofrontera submits study report of pharmacokinetics study to FDA by GlobeNewsWire
• Biofrontera reports financial results for the six months ended June 30, 2021 by GlobeNewsWire
• Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021 by GlobeNewsWire
• Biofrontera reports preliminary revenue for the month of July 2021 by GlobeNewsWire
• Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland by GlobeNewsWire
• Biofrontera Inc. seeks IPO in the USA by GlobeNewsWire
• Biofrontera provides update on clinical developments by GlobeNewsWire

Biofrontera AG ADS

BIOFRONTERA INC

• Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio by GlobeNewsWire
• Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities by GlobeNewsWire
• Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT by GlobeNewsWire
• Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update by GlobeNewsWire
• Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M by GlobeNewsWire
• Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025 by GlobeNewsWire
• Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG by GlobeNewsWire
• Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 by GlobeNewsWire
• Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program by GlobeNewsWire
• Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk by GlobeNewsWire

BIOGAIA AB

• BioGaia (Buy): Solid sales growth and confirmation that spending will slow by Carnegie Investment Bank AB (publ)
• BioGaia (Buy): Investing or overspending? by Carnegie Investment Bank AB (publ)
• BioGaia (Buy): Growth should return this quarter – Q2 preview by Carnegie Investment Bank AB (publ)
• BioGaia (Buy): Temporarily slower sales to pick up next quarter by Carnegie Investment Bank AB (publ)
• BioGaia (Buy): Attractive entry point despite a slower quarter – Q1 preview by Carnegie Investment Bank AB (publ)
• BioGaia (Buy): Unique combination of strong growth and high dividends by Carnegie Investment Bank AB (publ)
• BioGaia (Buy): Accelerating sales growth again – Q4 preview by Carnegie Investment Bank AB (publ)
• BioGaia (Buy): Great valuation support from 5–7% dividend yield by Carnegie Investment Bank AB (publ)
• BioGaia (Buy): Earnings to be pressured by large investments – Q3 preview by Carnegie Investment Bank AB (publ)
• BioGaia (Buy): Strong growth, while extra investments weigh on H2 earnings by Carnegie Investment Bank AB (publ)